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Background
HIV Natural Viral Suppressors (NVS) are individuals with
HIV-1 that are able to suppress HIV viral replication to
undetectable levels in the absence of antiretroviral ther-
apy. By contrast, Long-Term Nonprogressors (LTNP), rep-
resent individuals who are HIV-1 infected but who
maintain high CD4 counts over many years (no where in
the definition of LTNPs is viral load considered, and in
most series the HIV-1 viral loads range from 102 to 104
copies/ml) [1-3]. We present here a cohort of NVS, provid-
ing a case definition for identifying such individuals and
the results of preliminary evaluations.
Methods
Inclusion/Exclusion Criteria:
1. Confirmed HIV-1 by Western blot.
2. Positive HIV-1 Proviral DNA.
3. Viral loads <400 copies/ml at all time points for at least
a 2 year period and 4 viral load measurements (One viral
blip or viral load > 400 copies/ml during the above time
period was permitted if the subsequent viral loads were
<400).
4. No more than 2 weeks of antiretroviral (ART) use
(unless administered for pregnancy prophylaxis)
Studies included High Input PCR for Proviral DNA copy
number.
Results
35 patients were identified as NVS, and 22 have been
enrolled. Demographics are shown in Table 1.
Using a high-input assay developed specifically for this
cohort (limit of detection 1 copy/106 PBMCs), proviral
DNA copy number ranged from 1–74 copies/106 PBMCs
(refer to Figure 1). The mean proviral DNA copy number
was lower than both the controls we used in this study,
HIV progressors and individuals with low viral loads (Fig-
ure 1A). The later group consisted of HIV infected individ-
uals who had viral loads of 500–15,000 copies/ml, viral
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Table 1: Demographics of the NVS cohort
Age 51 (range 38–60)
Sex Male 64%, Female 36%
Race African American 100%
Median years with HIV 12 (range 2–19)
Median years viral suppression 5 (range 2–9)
Median of latest CD4 count (cells/ul) 887 (range 346–1564)
Average number of viral loads tested 13 (range 4–21)Retrovirology 2006, 3(Suppl 1):P55
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loads that are comparable to the majority of LTNPs.
Because some individuals in this group did not meet the
classic definition of LTNPs, we compared the mean HIV
proviral load of the NVS cohort to five published LTNP
cohorts, and the NVS cohort was consistently 1 to 2 logs
lower than that described in LTNPs, again confirming that
individuals classified as NVS did in fact demonstrate more
effective control of in vivo HIV-1 replication as reflected
by quantification of HIV DNA proviral copy number.
Conclusion
Patients with HIV-1 infection who are able to naturally
suppress HIV infection in the absence of therapy represent
one particular extreme of HIV infected patients. Although
it is too early to postulate on the factor or factors that
makes this group unique, there are likely multiple mech-
anisms involved in effective in vivo regulation of HIV
resulting in persistent non-therapeutic induced viral sup-
pression. The study of NVS, which represent a more
homologous group than LTNP in regards to HIV-1 sup-
pression, should lead to better understanding of the
immunoregulatory mechanisms involved. Studies are
underway to determine and further characterize the in
vivo mechanisms responsible for control of HIV-1 replica-
tion seen in Natural Viral Suppressors.
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A HIV-1 proviral copy numbers/106 cells Figure 1
A HIV-1 proviral copy numbers/106 cells. Progressors are individuals with HIV-1 viral loads >100,000 copies/ml. Low Vls are 
individuals with viral load of 500–15,000 copies/ml. B Mean HIV-1 proviral copy numbers/106 cells of the NVS cohort com-
pared to published data of LTNP cohorts [1,4-7].
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